229 related articles for article (PubMed ID: 11156365)
1. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity.
Krasnykh V; Dmitriev I; Navarro JG; Belousova N; Kashentseva E; Xiang J; Douglas JT; Curiel DT
Cancer Res; 2000 Dec; 60(24):6784-7. PubMed ID: 11156365
[TBL] [Abstract][Full Text] [Related]
2. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.
Kanerva A; Mikheeva GV; Krasnykh V; Coolidge CJ; Lam JT; Mahasreshti PJ; Barker SD; Straughn M; Barnes MN; Alvarez RD; Hemminki A; Curiel DT
Clin Cancer Res; 2002 Jan; 8(1):275-80. PubMed ID: 11801569
[TBL] [Abstract][Full Text] [Related]
3. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
Stoff-Khalili MA; Rivera AA; Glasgow JN; Le LP; Stoff A; Everts M; Tsuruta Y; Kawakami Y; Bauerschmitz GJ; Mathis JM; Pereboeva L; Seigal GP; Dall P; Curiel DT
Gene Ther; 2005 Dec; 12(23):1696-706. PubMed ID: 16034451
[TBL] [Abstract][Full Text] [Related]
4. Cancer-targeting gene therapy using tropism-modified adenovirus.
Tanaka T; Kuroki M; Hamada H; Kato K; Kinugasa T; Shibaguchi H; Zhao J; Kuroki M
Anticancer Res; 2007; 27(6A):3679-84. PubMed ID: 17970028
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids.
Grill J; Van Beusechem VW; Van Der Valk P; Dirven CM; Leonhart A; Pherai DS; Haisma HJ; Pinedo HM; Curiel DT; Gerritsen WR
Clin Cancer Res; 2001 Mar; 7(3):641-50. PubMed ID: 11297260
[TBL] [Abstract][Full Text] [Related]
6. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
Okegawa T; Sayne JR; Nutahara K; Pong RC; Saboorian H; Kabbani W; Higashihara E; Hsieh JT
J Urol; 2007 Mar; 177(3):1148-56. PubMed ID: 17296436
[TBL] [Abstract][Full Text] [Related]
7. New generation adenoviral vectors improve gene transfer by coxsackie and adenoviral receptor-independent cell entry.
Reynolds PN; Curiel DT
Kidney Int; 2002 Jan; 61(1 Suppl):S24-31. PubMed ID: 11841608
[TBL] [Abstract][Full Text] [Related]
8. Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor.
Kaner RJ; Worgall S; Leopold PL; Stolze E; Milano E; Hidaka C; Ramalingam R; Hackett NR; Singh R; Bergelson J; Finberg R; Falck-Pedersen E; Crystal RG
Am J Respir Cell Mol Biol; 1999 Mar; 20(3):361-70. PubMed ID: 10030833
[TBL] [Abstract][Full Text] [Related]
9. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors.
Wesseling JG; Bosma PJ; Krasnykh V; Kashentseva EA; Blackwell JL; Reynolds PN; Li H; Parameshwar M; Vickers SM; Jaffee EM; Huibregtse K; Curiel DT; Dmitriev I
Gene Ther; 2001 Jul; 8(13):969-76. PubMed ID: 11438831
[TBL] [Abstract][Full Text] [Related]
10. Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts.
Qin M; Chen S; Yu T; Escuadro B; Sharma S; Batra RK
Clin Cancer Res; 2003 Oct; 9(13):4992-9. PubMed ID: 14581374
[TBL] [Abstract][Full Text] [Related]
11. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer.
Miller CR; Buchsbaum DJ; Reynolds PN; Douglas JT; Gillespie GY; Mayo MS; Raben D; Curiel DT
Cancer Res; 1998 Dec; 58(24):5738-48. PubMed ID: 9865732
[TBL] [Abstract][Full Text] [Related]
12. Advances towards targetable adenovirus vectors for gene therapy.
Einfeld DA; Roelvink PW
Curr Opin Mol Ther; 2002 Oct; 4(5):444-51. PubMed ID: 12435045
[TBL] [Abstract][Full Text] [Related]
13. Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models.
Van Houdt WJ; Wu H; Glasgow JN; Lamfers ML; Dirven CM; Gillespie GY; Curiel DT; Haviv YS
Neuro Oncol; 2007 Jul; 9(3):280-90. PubMed ID: 17522331
[TBL] [Abstract][Full Text] [Related]
14. Development of PEGylated adenovirus vector with targeting ligand.
Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
[TBL] [Abstract][Full Text] [Related]
15. Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle.
Seidman MA; Hogan SM; Wendland RL; Worgall S; Crystal RG; Leopold PL
Mol Ther; 2001 Jul; 4(1):13-21. PubMed ID: 11472101
[TBL] [Abstract][Full Text] [Related]
16. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy.
Li Y; Pong RC; Bergelson JM; Hall MC; Sagalowsky AI; Tseng CP; Wang Z; Hsieh JT
Cancer Res; 1999 Jan; 59(2):325-30. PubMed ID: 9927041
[TBL] [Abstract][Full Text] [Related]
17. Biophysical targeting of adenovirus vectors for gene therapy.
Silman NJ; Fooks AR
Curr Opin Mol Ther; 2000 Oct; 2(5):524-31. PubMed ID: 11249755
[TBL] [Abstract][Full Text] [Related]
18. Novel adenoviral gene delivery system targeted against head and neck cancer.
Li D; Guang W; Abuzeid WM; Roy S; Gao GP; Sauk JJ; O'Malley BW
Laryngoscope; 2008 Apr; 118(4):650-8. PubMed ID: 18176343
[TBL] [Abstract][Full Text] [Related]
19. Targeted gene delivery by tropism-modified adenoviral vectors.
Douglas JT; Rogers BE; Rosenfeld ME; Michael SI; Feng M; Curiel DT
Nat Biotechnol; 1996 Nov; 14(11):1574-8. PubMed ID: 9634824
[TBL] [Abstract][Full Text] [Related]
20. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.
Zheng S; Ulasov IV; Han Y; Tyler MA; Zhu ZB; Lesniak MS
J Gene Med; 2007 Mar; 9(3):151-60. PubMed ID: 17351980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
